Reducing drug prices through increased regulation of pharmacy benefit managers (PBMs) is a priority for the U.S. Congress, according to the authors of a Perspective
After presenting the case of an older adult who had to prioritize treatment of severe tooth pain over medications for high blood pressure, authors write,
“Physicians take an oath to ‘do no harm,’” authors write in discussing the recent U.S. Supreme Court decision on affirmative action in college admissions. “The
“Continuation patents are becoming increasingly common in drug patent thickets, likely delaying or deterring generic competition, and thus potentially contributing to delays in patient access to
Compared with patients aged 60 to 64 years without Part D insurance, Medicare enrollees aged 65 to 74 years had more insulin fills, and more
“Growing resistance to vaccines, problems enforcing mandates, and judicial and legislative pressure for wide religious exemptions make it timely to reflect on the future of
Medications approved in the U.S. but not in other countries should be examined closely by health professionals and health systems before use, according to researchers
Of 210 new drugs approved by FDA from 2018 to 2021, 10% had null findings on 1 or more primary efficacy endpoints in pivotal trials,
The FDA last week dropped the emergency use authorization requirement that patients have positive test results before prescribing of the antiviral products ritonavir-boosted nirmatrelvir (Paxlovid)
FDA has concluded that a new regulatory pathway for cannabidiol (CBD) products is needed that balances individuals’ desire for access to CBD products with the